EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

A phase II study of ME2136 (Asenapine Maleate) plus standard antiemetic therapy for patients, including diabetic patients, receiving cisplatin-based chemotherapy

Satoshi Hamauchi, Hirofumi Yasui, Tomoya Yokota, Takahiro Tsushima, Kunihiro Fushiki, Tateaki Naito, Akira Ono, Nobuhiro Kado, Yusuke Onozawa, Haruyasu Murakami, Toshiaki Takahashi, Yasuyuki Hirashima und 2 weitere

Investigational New Drugs · 2024

DOI: 10.1007/s10637-024-01480-w ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Investigational New Drugs, 2024. Verfasst von Satoshi Hamauchi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan. Hauptthemen laut MEDLINE: Antiemetics, Cisplatin, Vomiting, Nausea. Die Arbeit nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Olanzapine combined with the neurokinin-1 receptor antagonist, palonosetron and dexamethasone is the standard treatment for chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). However, the use of olanzapine poses challenges in patients with diabetes mellitus (DM) due to the potential risk of hyperglycemia. ME2136, antipsychotic similar to olanzapine, is associated with a lower risk of hyperglycemia. This study investigated the antiemetic efficacy and safety of ME2136 for HEC. This single-arm phase 2 study examined the safety and efficacy of ME2136 5 mg for 4 days in combination with triplet-combination antiemetic therapy. Two cohorts were established for the safety assessment: DM and non-DM. Eligible patients had malignant tumors and were receiving cisplatin-based chemotherapy for the first time. The primary endpoint was the complete response (CR) rate, defined as the percentage of patients without vomiting and not requiring rescue medications in the delayed phase (24-120 h). Between December 2020 and January 2022, 40 patients were enrolled, with 20 in each cohort. All patients were included in the safety analysis and 35 in the efficacy analysis. The CR rate in the delayed phase was 71.4% [60% CI 63.1-78.6%] for all patients, 66.7% in the DM cohort, and 76.5% in the non-DM cohort. No treatment-related adverse events ≥ grade 3, including hyperglycemia, were reported. ME2136, when combined with standard triplet-combination antiemetic therapy, is expected to exert similar antiemetic effects to the standard treatment for CINV due to HEC. Currently, ME2136-02 trial is underway to examine the safety and efficacy of triplet-combination antiemetic therapy and a 5-day treatment with ME2136. This study was registered with the Japan Registry of Clinical Trials (jRCT2041200071) on 10 December 2020. Clinical trial registration: This study was registered with the Japan Registry of Clinical Trials (jRCT2041200071) on 10 December 2020.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntiemeticsCisplatinVomitingNauseaDibenzocycloheptenesHumansMaleMiddle AgedFemaleAgedAdultDexamethasoneDiabetes MellitusNeoplasmsDrug Therapy, CombinationAntineoplastic Combined Chemotherapy ProtocolsPalonosetron

Stichwörter der Autor:innen

Asenapine maleateCINVCisplatinME2136

Substanzen

AntiemeticsCisplatinDibenzocycloheptenesasenapineDexamethasonePalonosetron

Autor:innen und Institutionen

  • Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan.
  • Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagaizumi, Sunto-gun, Shizuoka, 411-8777, Japan. h.yasui@scchr.jp.
  • Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi, Japan.
  • Division of Gynecology, Shizuoka Cancer Center, Nagaizumi, Japan.
  • Division of Clinical Oncology, Shizuoka Cancer Center, Nagaizumi, Japan.
  • Clinical Trial Coordination Office, Shizuoka Cancer Center, Nagaizumi, Japan.

Zitieren

APA

Hamauchi, S., Yasui, H., Yokota, T., Tsushima, T., Fushiki, K., Naito, T., Ono, A., Kado, N., Onozawa, Y., Murakami, H., Takahashi, T., Hirashima, Y., Mori, K., & Yamazaki, K. (2024). A phase II study of ME2136 (Asenapine Maleate) plus standard antiemetic therapy for patients, including diabetic patients, receiving cisplatin-based chemotherapy. Investigational New Drugs. https://doi.org/10.1007/s10637-024-01480-w

Vancouver

Hamauchi S, Yasui H, Yokota T, Tsushima T, Fushiki K, Naito T, et al. A phase II study of ME2136 (Asenapine Maleate) plus standard antiemetic therapy for patients, including diabetic patients, receiving cisplatin-based chemotherapy. Investigational New Drugs. 2024. doi:10.1007/s10637-024-01480-w

BibTeX
@article{Hamauchi2024,
  author = {Hamauchi, Satoshi and Yasui, Hirofumi and Yokota, Tomoya and Tsushima, Takahiro and Fushiki, Kunihiro and Naito, Tateaki and Ono, Akira and Kado, Nobuhiro and Onozawa, Yusuke and Murakami, Haruyasu and Takahashi, Toshiaki and Hirashima, Yasuyuki and Mori, Keita and Yamazaki, Kentaro},
  title = {A phase II study of ME2136 (Asenapine Maleate) plus standard antiemetic therapy for patients, including diabetic patients, receiving cisplatin-based chemotherapy},
  journal = {Investigational New Drugs},
  year = {2024},
  doi = {10.1007/s10637-024-01480-w}
}
Kostenlos starten →